6.180USD+4.57%Mkt Cap: 334.88M USDP/E: —Last update: 2026-05-26
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinan…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap334.88M USD
Enterprise Value259.79M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-32.77M USD
Revenue/Share—
Last Price6.180 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.56
PEG—
EV/EBITDA-7.08
EV/Revenue—
P/S—
P/B6.58
EPS (TTM)-0.71
EPS (Forward)-0.88
52W Range
3.47539% of range10.42
52W High10.42 USD
52W Low3.475 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-58.39%
ROA-53.39%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.06M USD
CapEx (TTM)40.00K USD
FCF Margin—
FCF Yield-5.38%
Net Debt-51.12M USD
Net Debt/EBITDA1.39
Balance Sheet
Debt/Equity0.00
Current Ratio9.11
Quick Ratio8.98
Book Value/Sh0.8770 USD
Cash/Share0.9530 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 15, 2018
Splits
Last Split1:20
Split DateNov 15, 2018
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)15.50 USD
Target Range11.00 USD – 25.00 USD
# Analysts4
Ownership
Shares Out.53.88M
Float28.43M
Insiders27.74%
Institutions37.77%
Short Interest
Short Ratio26.3d
Short % Float13.55%
Short % Out.9.09%
Shares Short4.90M
Short (prev mo.)4.59M
Technical
SMA 506.475 (-4.6%)
SMA 2007.149 (-13.5%)
Beta0.99
S&P 52W Chg28.31%
Avg Vol (30d)157.86K
Avg Vol (10d)168.51K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—